Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy
Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
This non-randomized, open-label clinical trial is designed to determine safety and clinical
activity of a new chemotherapeutic agent, MAC-321, when given intravenously to patients with
non-small cell lung cancer. Clinical activity will be evaluated by determining the percentage
of patients with an objective tumor response after treatment with MAC-321. Patients must have
been previously treated with a platinum-containing chemotherapy regimen.
A total of 96 patients will be enrolled in this trial. Eligible patients will receive MAC-321
intravenously every 3 weeks for up to a total of 6 courses of treatment. All patients will
receive MAC-321 at the same dose. MAC-321 is an experimental drug, and is not offered outside
of this research trial.